ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1771

Role of Periostin in the Pathophysiology and Accurate Diagnosis of Interstitial Lung Disease Associated with Autoimmune Diseases

Verónica Pulito-Cueto1, David Iturbe-Fernández2, Victor Mora-Cuesta2, Joao Carlos Batista-Liz1, Belén Atienza-Mateo3, María Sebastián-Mora1, Virginia Portilla1, Alfonso Corrales1, Miguel A Gonzalez-Gay4, Jose Cifrian5, Ricardo Blanco1 and Raquel López-Mejías1, 1Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, 2Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, 3Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 4IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, 5Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain

Meeting: ACR Convergence 2023

Keywords: interstitial lung disease, Myopathies, rheumatoid arthritis, Sjögren's syndrome, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1734–1775) RA – Etiology and Pathogenesis Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Periostin is an extracellular matrix protein that contributes to the development and repair of lung tissue [1]. Previous works have described periostin as a key factor in the aberrant evolution of the airways and parenchymal fibrosis, being involved in the pathophysiology of different chronic lung diseases such as interstitial lung diseases (ILD) [1-3]. In this sense, ILD is one of the most frequent manifestations and the main cause of death in patients with autoimmune disease (AD), particularly in rheumatoid arthritis (RA), systemic sclerosis (SSc), inflammatory myopathies (IM) and Sjogren’s syndrome (SS) [4]. However, the accurate diagnosis of AD-ILD+ often remains a challenge due partially to the similarity with other diseases such as idiopathic pulmonary fibrosis (IPF) and interstitial pneumonia with autoimmune features (IPAF) [4].Accordingly, this work aimed to elucidate the role of periostin in the accurate diagnosis of AD-ILD+, as well as its relationship with molecules involved in the pathological process of vasculopathy and fibrosis typical of AD-ILD+.

Methods: Peripheral venous blood was collected from a total of 98 patients with AD-ILD+, a group composed of patients with RA‐ILD+ (n=33), SSc‐ILD+ (n=38), IM- ILD+ (n=23) and SS-ILD+ (n=4). Moreover, we recruited different comparative groups: 105 IPF patients, 11 IPAF patients and 43 healthy controls (HC). Serum levels of periostin were measured by enzyme-linked immunosorbent assay (ELISA). Additionally, serum levels of Krebs von den Lungen 6 (KL-6); interleukin 6 (IL-6); endothelin-1 (ET-1); vascular endothelial growth factor (VEGF) and intercellular adhesion molecule 1 (ICAM-1) were measured by ELISA.

Results: Patients with AD-ILD+ exhibited significantly higher periostin serum levels than IPF patients (p< 0.001, Figure 1A), whereas no difference was observed in relation to IPAF patients and HC (Figure 1A). Specifically, RA-ILD+ patients showed increased levels of periostin in relation to IPF patients (p< 0.001, Figure 1B). However, similar levels of periostin were found in patients with SSc-ILD+, IM-ILD+ as well as SS-ILD+ and those with IPF (Figure 1B). Furthermore, a positive correlation was discovered between periostin serum levels and VEGF serum concentrations in AD-ILD+ patients (p=0.01, Table 1). Nevertheless, periostin serum levels did not correlate with KL-6, IL-6, ET-1 and ICAM-1 levels in AD-ILD+ patients (Table 1).

Conclusion: Our findings suggest that circulating periostin could be considered a useful biomarker to discriminate RA-ILD+ from IPF, contributing to the accurate diagnosis of RA-ILD+. Furthermore, this work indicates a relationship of periostin with vascular dysfunction in AD-ILD+. References: [1] Cell Mol Life Sci.2017;74(23):4305-4314; [2] Respir Investig.2015;53(2):73-81; [3] PLoS One.2017;12(3):e0174547; [4] Expert Rev Clin Immunol.2018;14(1):69-82. Personal funds, VP-C: PI18/00042(ISCIII-ERDF); JB-L:FI22/00020(ISCIII-ESF); MSM-G:TRANSVAL22/01(IDIVAL); RL-M: CPII21/00004(ISCIII-ESF).

Supporting image 1

Figure 1. Role of periostin in the accurate diagnosis of AD-ILD+. A. Differences in periostin serum levels between patients with AD-ILD+ and those with IPF and IPAF, as well as HC; B. Differences in periostin serum levels between patients with AD-ILD+ stratified by the underlying AD and those with IPF. AD: autoimmune diseases; ILD: interstitial lung disease; IPF: idiopathic pulmonary fibrosis; IPAF: interstitial pneumonia with autoimmune features; HC: healthy controls; RA: rheumatoid arthritis; SSc: systemic sclerosis; IM: inflammatory myopathies; SS: sjögren syndrome. Significant results are highlighted in bold.

Supporting image 2


Disclosures: V. Pulito-Cueto: None; D. Iturbe-Fernández: None; V. Mora-Cuesta: None; J. Batista-Liz: None; B. Atienza-Mateo: None; M. Sebastián-Mora: None; V. Portilla: None; A. Corrales: None; M. Gonzalez-Gay: AbbVie/Abbott, 5, 6, Amgen, 5, 6, Pfizer, 5, 6; J. Cifrian: None; R. Blanco: AbbVie/Abbott, 5, 6, Amgen, 6, AstraZeneca, 2, Bristol-Myers Squibb(BMS), 6, Eli Lilly, 6, Galapagos, 2, 6, Janssen, 2, 6, Merck/MSD, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche, 5, 6, Sanofi, 6; R. López-Mejías: None.

To cite this abstract in AMA style:

Pulito-Cueto V, Iturbe-Fernández D, Mora-Cuesta V, Batista-Liz J, Atienza-Mateo B, Sebastián-Mora M, Portilla V, Corrales A, Gonzalez-Gay M, Cifrian J, Blanco R, López-Mejías R. Role of Periostin in the Pathophysiology and Accurate Diagnosis of Interstitial Lung Disease Associated with Autoimmune Diseases [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/role-of-periostin-in-the-pathophysiology-and-accurate-diagnosis-of-interstitial-lung-disease-associated-with-autoimmune-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/role-of-periostin-in-the-pathophysiology-and-accurate-diagnosis-of-interstitial-lung-disease-associated-with-autoimmune-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology